StockData
Transcode Therapeutics, Inc. logo

Transcode Therapeutics, Inc. (RNAZ) shareholders

RNAZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$1.41+0.06 (+4.44%)

Close on Nov 17, 2026Market cap $1.43MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
0.2%
0M of 17M shares
Institutional holders
8
2 new, 2 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Defj, LLC
Joint filing with CK Life Sciences Int'l., (Holdings) Inc. (83.90%)
14,134,48183.90%13D (active) amendmentAug 3, 2026
Thomas A. Fitzgerald422,0365.50%13D (active)Jun 21, 2024
Unleash Immuno Oncolytics, Inc.300,0009.94%13G (passive)Jul 23, 2026
Elena Rosa Braci186,2366.17%13G (passive)Jul 23, 2026
Daniel Eduardo Katzman155,6115.16%13G (passive)Jul 23, 2026
SC-Sigma Global Partners, LP
Joint filing with YA II PN, Ltd. (9.90%), YA Global Investments II (U.S.), LP (9.90%) and 5 more
101,7729.90%13G (passive)Apr 15, 2026
CK Life Sciences Int'l., (Holdings) Inc.
Joint filing with Defj, LLC (9.10%)
83,2859.10%13D (active) amendmentOct 27, 2025
Hal Mintz
Joint filing with Sabby Management, LLC (9.90%), Sabby Volatility Warrant Master Fund Ltd (9.90%)
69,5559.90%13G (passive)Dec 31, 2024
Thomas Joseph Tracy35,0005.00%13D (active)Mar 7, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of RNAZValueChange% of portfolio
Yorkville Advisors Global, LP19,6390.12%$121.96KNew0.14%
Vanguard Capital Management LLC6,5450.04%$40.64K–0.00%
Vanguard Fiduciary Trust Co2,9820.02%$18.52K–0.00%
UBS Group AG2,8880.02%$17.93K−5,4070.00%
FMR LLC7060.00%$4.38KNew0.00%
Tower Research Capital LLC (TRC)6770.00%$4.20K+4490.00%
Wells Fargo & Company/Mn550.00%$342–0.00%
SBI Securities Co., Ltd.120.00%$75–0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202680M0.2%2 / 11 / 20M0M
Q1 202680M0.2%4 / 21 / 20M0M
Q4 202560M0.0%1 / 10 / 30M0M
Q3 202580M0.1%3 / 02 / 40M0M
Q2 202590M0.2%1 / 44 / 110M0M
Q1 2025190M0.5%14 / 30 / 00M0M
Q4 202450M0.0%5 / 00 / 00M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

5 funds held RNAZ in Q2 2026, 40% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of RNAZValue% of fundAs of
Fidelity Extended Market Index Fund8,4920.05%$43.65K0.00%May 31, 2026
Vanguard Extended Market Index Fund6,5450.04%$40.64K0.00%Jun 30, 2026
Fidelity Series Total Market Index Fund1,1800.01%$6.07K0.00%May 31, 2026
Fidelity Total Market Index Fund5100.00%$2.62K0.00%May 31, 2026
Blackstone Alternative Multi-Strategy Fund-199-0.00%-$1.24K-0.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Thomas A. FitzgeraldChief Financial Officer, Director56,3180.33%Sep 11, 2026
John A. TattoryInterim CFO––Sep 21, 2026
Jack E. StoverDirector––Dec 22, 2025
Elizabeth CzerepakDirector––Dec 22, 2025
Life Sciences Intl (Holdings) Inc CK10% owner12,113,89971.55%Aug 5, 2026
Defj, Llc10% owner––Aug 5, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Life Sciences Intl (Holdings) Inc CK
10% owner
Aug 3, 2026Conversion+11,813,859––12,113,899
Life Sciences Intl (Holdings) Inc CK
10% owner
Aug 3, 2026Conversion+2,020,582––14,134,481
Robert Michael Dudley
Chief Executive Officer, Director
Sep 28, 2023Buy+98,000$0.51$49.98K180,262
Thomas A. Fitzgerald
Chief Financial Officer, Director
Sep 28, 2023Buy+49,350$0.51$25.17K56,318
Robert Michael Dudley
Chief Executive Officer, Director
Jun 21, 2023Buy+12,000$2.65$31.80K82,262
Robert Michael Dudley
Chief Executive Officer, Director
Jun 20, 2023Buy+6,607$2.55$16.85K70,262
Robert Michael Dudley
Chief Executive Officer, Director
Jun 9, 2023Buy+19,000$2.76$52.44K61,155
Robert Michael Dudley
Chief Executive Officer, Director
Jun 9, 2023Buy+19,000$2.76$52.44K912,114
Robert Michael Dudley
Chief Executive Officer, Director, 10% owner
Sep 14, 2022Buy+20,000$1.15$23.00K893,114
Thomas A. Fitzgerald
Chief Financial Officer, Director
Jun 16, 2022Buy+12,000$1.27$15.24K139,377
Robert Michael Dudley
Chief Executive Officer, Director, 10% owner
May 31, 2022Buy+2,000$1.87$3.74K873,114
Robert Michael Dudley
Chief Executive Officer, Director, 10% owner
May 27, 2022Buy+28,000$1.84$51.52K871,114

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
5.14%
0M shares short
Days to cover
2.0
At 0M shares a day
Change since last report
-5.4%
From 0M shares
Short volume, 20 days
45.8%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Transcode Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 22,384 shares on Aug 20, 2026 over the last 90 days.

See a number that looks wrong?